Annexon, Inc. (NASDAQ:ANNX) EVP Dean Richard Artis Sells 5,515 Shares of Stock

Annexon, Inc. (NASDAQ:ANNX) EVP Dean Richard Artis sold 5,515 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $2.97, for a total transaction of $16,379.55. Following the sale, the executive vice president now owns 83,814 shares in the company, valued at $248,927.58. This represents a 6.17 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Annexon Stock Down 0.7 %

Annexon stock opened at $2.83 on Friday. Annexon, Inc. has a 12-month low of $2.63 and a 12-month high of $8.40. The stock has a market cap of $301.66 million, a price-to-earnings ratio of -2.70 and a beta of 1.07. The business’s 50-day simple moving average is $4.29 and its 200 day simple moving average is $5.57.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ANNX. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price objective on shares of Annexon in a report on Friday, November 15th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Annexon in a report on Tuesday, December 17th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $15.80.

Institutional Investors Weigh In On Annexon

Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. grew its holdings in Annexon by 16.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,706,182 shares of the company’s stock worth $10,101,000 after acquiring an additional 235,810 shares during the period. Geode Capital Management LLC grew its stake in shares of Annexon by 18.3% during the third quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company’s stock worth $12,693,000 after purchasing an additional 331,269 shares during the period. Barclays PLC increased its holdings in Annexon by 212.0% in the third quarter. Barclays PLC now owns 177,765 shares of the company’s stock valued at $1,052,000 after purchasing an additional 120,789 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Annexon by 221.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 732,216 shares of the company’s stock valued at $4,335,000 after buying an additional 504,656 shares during the period. Finally, FMR LLC boosted its holdings in Annexon by 3.2% during the third quarter. FMR LLC now owns 8,561,949 shares of the company’s stock worth $50,687,000 after buying an additional 262,229 shares during the last quarter.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.